Concurrently, the PI3K-AKT-mTOR pathway is aberrantly activated in prostate cancer, driving tumor growth and treatment resistance by regulating proliferation, survival, and metabolic reprogramming. This evidence concerns the gene MTOR and prostate carcinoma.